Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1667899

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1667899

Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Disease Indication, By End-User, By Region and Competition, 2020-2030F

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

The Global Conjugate Vaccine Market was valued at USD 19.69 billion in 2024 and is projected to reach USD 34.10 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.56%. This significant market expansion is driven by the increasing recognition of preventive healthcare. Governments and healthcare organizations globally are focused on improving immunization coverage to reduce the prevalence of infectious diseases such as pneumococcal infections, Haemophilus influenzae type b (Hib), and meningococcal diseases. Rising global healthcare spending and the prioritization of vaccination programs in both developed and developing nations have created a favorable environment for market growth. Additionally, the demand for vaccines targeting multiple pathogens in a single formulation has spurred the development of multivalent conjugate vaccines, which offer comprehensive protection while enhancing cost-effectiveness. The growing awareness of vaccines' role in preventing life-threatening diseases, particularly among vulnerable populations like infants and the elderly, has further contributed to market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 19.69 Billion
Market Size 2030USD 34.10 Billion
CAGR 2025-20309.56%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

Increasing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare is a crucial factor driving the expansion of the Global Conjugate Vaccine Market. In recent years, there has been a notable shift from a curative to a preventive healthcare approach. This shift is supported by the understanding that preventing diseases through vaccination is more cost-effective and less burdensome on individuals and healthcare systems than treating illnesses after they occur.

Key Market Challenges

High Manufacturing Costs

The manufacturing complexity of conjugate vaccines arises from their unique composition. These vaccines combine a weak antigen with a potent one to generate a stronger immune response. Achieving this requires advanced biotechnological techniques and strict quality control throughout production. Additionally, rigorous regulatory requirements further contribute to the overall production cost. High manufacturing costs limit the accessibility of conjugate vaccines, especially in low- and middle-income countries, where budget constraints often hinder vaccine procurement and affordability. Even in developed countries with robust healthcare systems, the high cost of conjugate vaccines can pose challenges, potentially deterring healthcare providers and individuals from prioritizing these vaccines, despite their proven efficacy.

Key Market Players

  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt. Ltd
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

Report Scope

This report segments the Global Conjugate Vaccine Market by the following categories, along with detailed insights into industry trends:

By Product Type:

  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines

By Disease Indication:

  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid

By End-User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

By Region:

  • North America:
  • United States
  • Canada
  • Mexico
  • Europe:
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America:
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa:
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

The competitive landscape includes detailed profiles of the major companies operating in the Global Conjugate Vaccine Market.

Available Customizations

TechSci Research offers customizations for the Global Conjugate Vaccine Market report to suit specific business needs. Customization options include:

  • Detailed analysis and profiling of up to five additional market players.
Product Code: 19075

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Conjugate Vaccine Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
    • 4.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
    • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Disease Indication
    • 4.3.3. By End-User
    • 4.3.4. By Region

5. Asia Pacific Conjugate Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Disease Indication
    • 5.2.3. By End-User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Conjugate Vaccine Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Disease Indication
        • 5.3.1.2.3. By End-User
    • 5.3.2. India Conjugate Vaccine Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Disease Indication
        • 5.3.2.2.3. By End-User
    • 5.3.3. Australia Conjugate Vaccine Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Disease Indication
        • 5.3.3.2.3. By End-User
    • 5.3.4. Japan Conjugate Vaccine Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Disease Indication
        • 5.3.4.2.3. By End-User
    • 5.3.5. South Korea Conjugate Vaccine Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Disease Indication
        • 5.3.5.2.3. By End-User

6. Europe Conjugate Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Disease Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Conjugate Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Disease Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Germany Conjugate Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Disease Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Spain Conjugate Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Disease Indication
        • 6.3.3.2.3. By End-User
    • 6.3.4. Italy Conjugate Vaccine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Disease Indication
        • 6.3.4.2.3. By End-User
    • 6.3.5. United Kingdom Conjugate Vaccine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Disease Indication
        • 6.3.5.2.3. By End-User

7. North America Conjugate Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Disease Indication
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Conjugate Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. Mexico Conjugate Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. Canada Conjugate Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By End-User

8. South America Conjugate Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Disease Indication
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Conjugate Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. Argentina Conjugate Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Colombia Conjugate Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By End-User

9. Middle East and Africa Conjugate Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Disease Indication
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Conjugate Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. Saudi Arabia Conjugate Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. UAE Conjugate Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By End-User
    • 9.3.4. Egypt Conjugate Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By End-User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Conjugate Vaccine Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Sanofi S.A
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Merck & Co. Inc.
  • 14.4. GlaxoSmithKline plc
  • 14.5. Bharat Biotech International Limited
  • 14.6. Serum Institute of India Pvt. Ltd
  • 14.7. Biological E. Limited
  • 14.8. Bavarian Nordic A/S
  • 14.9. CSL Limited
  • 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!